A random urine test panel aids in diagnosing mast cell activation syndrome (MCAS), a complex condition often misdiagnosed due to overlapping symptoms. The panel improves access, speeds up diagnosis, and enables individualized treatment by detecting key mast cell mediators.

At this year's Classical Hematology Conference we will be joined by Hematology experts, Adam Cuker, M.D. and Stephan Moll, M.D. Reserve your spot today.

William Morice II, M.D., Ph.D., highlights data-driven reasons health systems benefit from the lab service line and strategies to bolster performance.

In July 2022, Mayo Clinic Laboratories announced fifteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

John Osborn, operations administrator in the Department of Laboratory Medicine and Pathology at Mayo Clinic, joins the "Answers From the Lab" podcast for a discussion with host Bobbi Pritt, M.D. about monkeypox testing. In this episode, John and Dr. Pritt discuss how Mayo Clinic swiftly operationalized monkeypox testing and the challenges involved with supporting the new assay, including staffing.

Todd Walker is a laboratory supervisor for Mayo Clinic Laboratories, Specimen Operations, where he helps lead the department that serves as the gateway between collecting and delivering specimens and getting them processed. Todd credits his diverse, agile team and the impressive global logistics infrastructure that allows them to support the processing of 40,000 specimens in a day.

Rajiv Pruthi, M.B.B.S., explains how Mayo Clinic Laboratories’ serotonin release assay achieves high sensitivity and specificity while avoiding the use of radioactive materials. Serotonin release testing is an important tool in the diagnosis of heparin induced thrombocytopenia, or HIT, which can have devastating consequences for patients.

This week's research roundup features: Gastrointestinal stromal tumors mimicking gynecologic disease: clinicopathological analysis of 20 cases.

This page includes updates posted to mayocliniclabs.com during the month of July.

In this month's "Hot Topic," Rajiv Pruthi, M.B.B.S., discusses heparin induced thrombocytopenia (HIT), approach diagnosis, and the role of the functional serotonin release assay (SRA).

Topic highlights include: Mayo Clinic in Rochester again ranked country's top hospital: U.S. news and world report, WHO declares monkeypox a global health emergency as infections soar, Depression is likely not caused by a chemical imbalance in the brain, study says.

William Morice II, M.D., Ph.D., president of Mayo Clinic Laboratories, shares his concerns about the VALID Act, which if passed would give the FDA oversight of laboratory-developed tests. VALID could hamper labs’ test development activity, increase costs for labs, and disproportionately affect smaller labs or those with fewer resources. It could also lead to more test development partnerships and lab collaboration.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with podcast host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss the World Health Organization’s declaration of monkeypox as a global public health emergency, how Mayo Clinic Laboratories quickly implemented testing, and the public-private partnership to manage the response.

Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for managing clinical care.

This week's research roundup features: Motor-neuron-disease-like phenotype associated with IgLON5 disease.